Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22712661 | 0.97 | MGLL (0.37) | MGLLALOX12DGKAPSMB8PSMB5 | |
| SCHEMBL28342168 | 0.95 | DGKA (0.40) | MGLLALOX12DGKAPSMB8PSMB5 | |
| SCHEMBL28192296 | 0.95 | DGKA (0.40) | MGLLALOX12DGKAPSMB8PSMB5 | |
| SCHEMBL1869815 | 0.93 | ADRA2A (0.33) | MGLLALOX12PSMB8PSMB5MAPT | |
| SCHEMBL15760609 | 0.92 | PRKCA (0.33) | MGLLALOX12DGKAPSMB8PSMB5 | |
| SCHEMBL7954092 | 0.92 | DGKA (0.40) | ALOX12DGKAPSMB8PSMB5BRD4 | |
| SCHEMBL12285169 | 0.91 | EPHX2 (0.38) | MGLLALOX12DGKAPSMB8PSMB5 | |
| SCHEMBL4902271 | 0.90 | MGLL (0.33) | MGLLALOX12MAPTMAPK1RECQL | |
| Ethylene Glycol SCHEMBL6523939 | 0.88 | PSMB8 (0.34) | MGLLALOX12PSMB8PSMB5PRKCA | |
| SCHEMBL9972406 | 0.87 | DGKA (0.37) | ALOX12DGKAPSMB8PSMB5BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118105543-A | Vancomycin-carrying hydrogel porous surgical implant for treating infectious bone defect and preparation method thereof | 山东大学齐鲁医院 | 2024-05-31 | — | — | CN | claimed |
| EP-4291256-A1 | TWO COMPONENT SEALING SYSTEMS INCLUDING SYNTHETIC MATRICES AND BIOSYNTHETIC ADHESIVES | Ethicon, Inc (US) | 2023-12-20 | — | — | EP | claimed |
| US-11826028-B2 | Two component sealing systems including synthetic matrices and biosynthetic adhesives for sealing resected surfaces of organs to control bleeding, fluid leaks and air leaks | ETHICON, INC. (US) | 2023-11-28 | — | — | US | claimed |
| US-20210393245-A1 | TWO COMPONENT SEALING SYSTEMS INCLUDING SYNTHETIC MATRICES AND BIOSYNTHETIC ADHESIVES FOR SEALING RESECTED SURFACES OF ORGANS TO CONTROL BLEEDING, FLUID LEAKS AND AIR LEAKS | ETHICON, INC. | 2021-12-23 | — | — | US | claimed |
| CN-106117340-B | Tumor necrosis factor β analog, its conjugate and its medical usage | 岳阳新华达制药有限公司 | 2019-10-25 | — | — | CN | claimed |
| CN-106693039-B | A kind of preparation method of the medical aquogel with good biological adhesiveness | 南开大学 | 2019-10-01 | — | — | CN | claimed |
| US-20190269819-A1 | SEALANT FOAM COMPOSITIONS FOR LUNG APPLICATIONS | CILAG GMBH INTERNATIONAL (CH) | 2019-09-05 | — | — | US | claimed |
| CN-105294852-B | The conjugate and its medical usage of polyethylene glycol and tumor necrosis factor α or its analog | 岳阳新华达制药有限公司 | 2019-06-07 | — | — | CN | claimed |
| CN-109758675-A | A kind of self-healing medical gel | 青岛中腾生物技术有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-108014365-A | A kind of sealer hydrogel and its kit and preparation method | 沈伟 | 2018-05-11 | — | — | CN | claimed |
| CN-1984924-B | Methods for increasing conjugation of protein and polyethylene glycol (PEG) | ANTICANCER INC | 2011-08-10 | — | — | CN | claimed |
| US-20080267902-A1 | BLOOD PRODUCTS WITH BINDING AGENT | BIOMET MICROFIXATION, LLC | 2008-10-30 | — | — | US | claimed |
| CN-1984924-A | Methods for increasing conjugation of protein and polyethylene glycol (PEG) | ANTICANCER INC (US) | 2007-06-20 | — | — | CN | claimed |
| CN-1756571-A | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | claimed |
| EP-1583561-A3 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2005-12-07 | — | — | EP | claimed |
| EP-1583561-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2005-10-12 | — | — | EP | claimed |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-04 | — | — | US | claimed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | claimed |
| EP-0754065-A1 | CELL-GELS | COLLAGEN CORPORATION (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026761-A1 | CELL-GELS | COLLAGEN CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | CD44, SELP, EPCAM | MGLL 943/4885ALOX12 319/4885DGKA 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.